| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 123.45M | 132.98M | 160.01M | 209.98M | 170.91M | 96.88M |
| Gross Profit | 6.62M | 1.26M | 3.27M | 6.24M | 11.65M | 10.47M |
| EBITDA | -3.87M | -5.97M | -9.52M | -9.91M | -5.42M | 5.30M |
| Net Income | -5.50M | -7.96M | -11.47M | -11.54M | -6.39M | 3.59M |
Balance Sheet | ||||||
| Total Assets | 26.92M | 25.85M | 35.30M | 71.20M | 58.73M | 33.86M |
| Cash, Cash Equivalents and Short-Term Investments | 6.52M | 2.18M | 1.25M | 16.72M | 21.25M | 18.24M |
| Total Debt | 1.85M | 2.22M | 2.40M | 5.74M | 7.98M | 3.69M |
| Total Liabilities | 11.22M | 8.93M | 10.08M | 33.74M | 19.04M | 15.12M |
| Stockholders Equity | 15.71M | 16.91M | 25.20M | 37.43M | 39.68M | 18.74M |
Cash Flow | ||||||
| Free Cash Flow | 4.85M | 666.22K | -13.51M | -13.33M | -20.02M | 6.77M |
| Operating Cash Flow | 4.96M | 790.18K | -13.49M | -11.99M | -18.03M | 6.89M |
| Investing Cash Flow | -121.17K | -123.96K | -42.38K | -1.34M | -6.64M | -116.75K |
| Financing Cash Flow | 488.43K | -18.00K | -1.63M | 9.94M | 27.21M | 10.79M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% | |
54 Neutral | $5.28M | -0.85 | ― | ― | -16.89% | 31.24% | |
49 Neutral | $18.31M | ― | -11.43% | ― | -12.53% | -3.24% | |
44 Neutral | $7.74M | ― | ― | ― | -35.95% | 26.08% | |
44 Neutral | $23.93M | -11.97 | 12.11% | ― | 570.49% | ― | |
40 Underperform | $3.55M | -0.27 | -373.22% | ― | -39.99% | -26.44% |
In a Form 6-K filing for December 2025, Jowell Global reported unaudited financial results for the first half of 2025, covering the period ended June 30, 2025. Total revenues declined 11.1% year over year to $76.2 million as the weighted average unit price nearly halved, but revenue from health and nutritional supplements surged 245.4% to $59.4 million, offset by steep declines in cosmetic and household product sales as the company deliberately scaled back low-margin categories. Total costs and operating expenses fell 13.3% to $77.7 million, driven by reduced costs of revenues and lower marketing spend, though fulfillment costs rose sharply amid higher package delivery volumes. Operating loss narrowed by 60.6% to $1.6 million, and net loss shrank 66.4% to $1.3 million, reflecting the benefits of the product mix shift and cost controls. As of June 30, 2025, Jowell held about $6.5 million in cash and $8.7 million in working capital through its China-based VIE, and management indicated that existing cash, ongoing sales and its effective shelf registration are expected to support liquidity needs for at least the next 12 months.
The most recent analyst rating on (JWEL) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Jowell Global stock, see the JWEL Stock Forecast page.
Jowell Global Ltd., a Cayman Islands company, announced the termination of a Securities Purchase Agreement with Jowell Holdings Ltd. on November 11, 2025. This agreement, initially established on October 14, 2025, involved the sale of 2,000,000 ordinary shares but was not closed. Subsequently, on November 14, 2025, Jowell Global entered into a Promissory Note Purchase Agreement with Jowell Holdings, selling a promissory note valued at $2,800,000 with a 4% annual interest rate, maturing in 36 months. These strategic moves indicate a shift in financing strategy and could impact the company’s financial structure and stakeholder relations.
The most recent analyst rating on (JWEL) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Jowell Global stock, see the JWEL Stock Forecast page.